6883 688399 30 May 2022 | Other | ¥10 Per Share |
6883 688399 23 Jun 2021 | Other | ¥5.5 Per Share |
6883 688399 25 Sep 2020 | Other | ¥1.5 Per Share |
6883 688399 22 Jun 2020 | Other | ¥1.5 Per Share |
23 May 2025 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
6883 688399 30 May 2022 | Other | ¥10 Per Share |
6883 688399 23 Jun 2021 | Other | ¥5.5 Per Share |
6883 688399 25 Sep 2020 | Other | ¥1.5 Per Share |
6883 688399 22 Jun 2020 | Other | ¥1.5 Per Share |
23 May 2025 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Guoqiang Wang CEO | SSE Exchange | CNE1000055B2 ISIN |
CN Country | 684 Employees | - Last Dividend | 13 Jun 2025 Last Split | - IPO Date |
Jiangsu Bioperfectus Technologies Co., Ltd. is a prominent figure in the molecular diagnostics field, dedicated to enhancing healthcare through innovative diagnostics solutions. Since its inception in 2010, the company has been deeply involved in the research, development, manufacturing, and marketing of in vitro diagnostic (IVD) products within China. Based in Taizhou, China, Bioperfectus stands out for its commitment to developing diagnostic technologies that address a wide range of infectious diseases and other medical conditions, aiming to deliver accurate, efficient, and reliable solutions for professionals and patients alike.
Jiangsu Bioperfectus Technologies Co., Ltd. provides a comprehensive array of products and services in the molecular diagnostics landscape: